Clinical Trial

Effect of AI-Assisted Expressive Writing on Anxiety, Emotional Distress, and Quality of Life Among Patients Receiving Chemotherapy

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 20, 2026 (before its estimated August 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the effect of an AI-assisted expressive writing intervention on anxiety, emotional distress, and quality of life among patients receiving chemotherapy. A mixed-methods, interventional research design will be employed. Participants will be assigned to either a study group receiving the AI-assisted expressive writing program in addition to routine care or a control group receiving routine care only. Quantitative data will be collected using the Depression Anxiety Stress Scale-21 (DASS-21) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Qualitative data will be obtained through semi-structured interviews to explore participants' experiences with the intervention. The findings are expected to provide evidence regarding the effectiveness of AI-assisted expressive writing as a supportive strategy for improving psychological well-being and quality of life among patients undergoing chemotherapy.
Trial Details
NCT Number NCT07713381
Lead Sponsor Alexandria University
Conditions Cancer, Chemotherapy, Anxiety
Enrollment 100 participants
Start Date 2026-07-10
Primary Completion 2026-08-10 (estimated)
Study Completion 2026-09-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-20